Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate vs Deferred Indinavir in HIV
NCT00000861Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indinavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Disease progression or death. Status: completed.
02
Drugs
indinavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000861.